Strengthening Its Position Within Strasbourg’s Leading Biotech Ecosystem.
In 2022, Odimma Therapeutics relocated its headquarters to PH8, Strasbourg’s business incubator dedicated to health technologies, strategically located alongside the University Hospital of Strasbourg and the city’s emerging Nextmedinnovation campus.
This move places Odimma at the heart of one of France’s most dynamic life sciences ecosystems, fostering closer collaboration with clinicians, researchers and biotechnology innovators while increasing the company’s international visibility.
Odimma continues to maintain its research laboratory at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS), where its scientific teams pursue the development of next-generation personalized cancer immunotherapies.
The relocation reflects Odimma’s commitment to building strong academic, clinical and industrial partnerships that accelerate innovation in precision oncology.
